Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Mylan Products Ltd, Station Close, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom
Pharmacotherapeutic group: Nervous system, parasympathomimetics, anticholinesterases, pyridostigmine
ATC code: N07AA02
Mestinon is an antagonist to cholinesterase, the enzyme which normally destroys acetylcholine. The action of Mestinon can briefly be described, therefore, as the potentiation of naturally occurring acetylcholine. Mestinon has a more prolonged action than Prostigmin (neostigmine) although it is somewhat slower to take effect (generally taking 30–60 minutes). Because it has a weaker “muscarinic” action than Prostigmin, it is usually much better tolerated by myasthenic patients in whom the longer action is also an advantage.
Oral pyridostigmine bromide is poorly absorbed. Maximum plasma concentrations occur at 1 to 2 hours and it is eliminated by the kidney largely unchanged with a half-life of 3 to 4 hours.
There are no preclinical data of relevance to the prescriber, which are additional to those already included in other sections of the SmPC.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
